Ignite Creation Date:
2024-10-26 @ 3:39 PM
Last Modification Date:
2024-10-26 @ 3:39 PM
Study NCT ID:
NCT06586580
Status:
COMPLETED
Last Update Posted:
None
First Post:
2024-09-04
Brief Title:
Treatment of Metastatic Melanoma with Lenvatinib Anti-PD1
Sponsor:
None
Organization:
None
Study Overview
Official Title:
Le Traitement Par Lenvatinib Anti-PD1 Du Mélanome Métastatique
Status:
COMPLETED
Status Verified Date:
2024-09
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
No
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
LENVAMEL
Brief Summary:
The hypothesis is that treatment with Lenvatinib Pembrolizumab is less effective in real life than in clinical trials In fact an objective response rate lt 20 and a worse tolerability of the treatment in real life with 50 of severe toxicities are expected
Detailed Description:
None
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None